journal article·2022-11-14Open access

Management of Severe Asthma in Eosinophilic Granulomatosis with Polyangiitis with Interleukin-5-Targeted Therapies: Current Status and Report of Two Cases

Ciro Romano, Domenico Cozzolino, Ausilia Sellitto, Luca Rinaldi

Applied Sciences· Volume 12· Issue 22

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic disorder characterized by peripheral eosinophilia, severe eosinophilic asthma, sinusitis, transient pulmonary infiltrates, and features of medium/small-vessel vasculitis. EGPA belongs to the group of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides, although only 30 to 40% of patients display ANCA positivity, which is mainly of myeloperoxidase (MPO) specificity. Particularly, ANCA-positive patients typically show vasculitic features. Interleukin (IL)-5 has been demonstrated to play a crucial role in determining eosinophilic airway inflammation in EGPA patients. Specifically, maturation, activation, and survival of eosinophils especially depend on IL-5 availability. Therefore, blocking IL-5 biological activity may be a rewarding strategy for control of eosinophilic inflammation. Several monoclonal antibodies with the ability to interfere with the biological activity of IL-5 have been developed, namely, mepolizumab, reslizumab, and benralizumab. Here, we discuss the role of these drugs in the management of severe eosinophilic asthma in the context of EGPA and report the outcome of two EGPA patients with severe eosinophilic asthma treated at our outpatient clinic.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Vasculitis and related conditions · Eosinophilic Disorders and Syndromes · Urticaria and Related Conditions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Clinical Immunology Outpatient Clinic, Division of Internal Medicine, Department of Advanced Medical and Surgical Sciences, “Luigi Vanvitelli” University of Campania, 80131 Naples, Italy

Cardiology Outpatient Clinic, Division of Internal Medicine, Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, 80131 Naples, Italy

Division of Internal Medicine, Department of Advanced Medical and Surgical Sciences, “Luigi Vanvitelli” University of Campania, 80131 Naples, Italy

References (50)

Show source-provided references
1. Almaani, S., Fussner, L.A., Brodsky, S., Meara, A.S., and Jayne, D. (2021). ANCA-Associated Vasculitis: An Update. J. Clin. Med., 10.10.3390/jcm10071446 ↗
2. ANCA-associated vasculitis10.1038/s41572-020-0204-y ↗
3. Anti-neutrophil cytoplasmic autoantibodies: Methodological aspects and clinical significance in systemic vasculitis10.1016/j.autrev.2012.08.008 ↗
4. ANCA-associated vasculitis—Clinical utility of using ANCA specificity to classify patients10.1038/nrrheum.2016.123 ↗
5. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides10.1002/art.37715 ↗
6. Vasculitides: Proposal for an integrated nomenclature10.1016/j.autrev.2015.10.008 ↗
7. Koike, H., Nishi, R., Yagi, S., Furukawa, S., Fukami, Y., Iijima, M., and Katsuno, M. (2022). A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis. Adv. Ther., online ahead of print.10.1007/s12325-022-02307-x ↗
8. French Vasculitis Study Group. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis study group cohort10.1002/art.37721 ↗
9. Vasculitis for the internist: Focus on ANCA-associated vasculitis10.1007/s11739-017-1683-z ↗
10. A Review of Primary Vasculitis Mimickers Based on the Chapel Hill Consensus Classification10.1155/2020/8392542 ↗
11. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis10.1136/annrheumdis-2021-221794 ↗
12. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis10.1002/acr.24634 ↗
13. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients10.1097/00005792-199601000-00003 ↗
14. The Five-Factor Score revisited: Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort10.1097/MD.0b013e318205a4c6 ↗
15. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis10.1002/acr.24596 ↗
16. (2022, October 23). Diagnosis and Management of Difficult-to-Treat & Severe Asthma—Global Initiative for Asthma—GINA (ginasthma.org). Available online: https://ginasthma.org/severeasthma/.
17. Biologics in allergic and immunologic diseases: Promises and challenges in the era of personalized medicine10.1016/j.anai.2018.01.032 ↗
18. The use of biologics for immune modulation in allergic disease10.1172/JCI124607 ↗
19. EAACI Biologicals Guidelines—Recommendations for severe asthma10.1111/all.14425 ↗
20. (2022, October 23). Nucala, INN-Mepolizumab (Europa.eu). Available online: https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf.
21. Sustained response to mepolizumab in refractory Churg-Strauss syndrome10.1016/j.jaci.2009.10.014 ↗
22. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome10.1016/j.jaci.2010.03.028 ↗
23. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome10.7326/0003-4819-155-5-201109060-00026 ↗
24. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome
25. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis10.1056/NEJMoa1702079 ↗
26. A disease-specific activity index for Wegener’s granulomatosis: Modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5 ↗
27. Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis10.1186/s13075-021-02462-6 ↗
28. Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: A retrospective study10.1186/s13075-022-02845-3 ↗
29. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis10.1016/j.ejim.2021.08.021 ↗
30. Low-Dose Mepolizumab Effectiveness in Patients Suffering from Eosinophilic Granulomatosis with Polyangiitis10.4168/aair.2020.12.5.885 ↗
31. Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis: Data from a European Collaborative Study10.1002/art.41534 ↗
32. Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase10.1016/j.jaip.2020.09.025 ↗
33. Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis: A European Multicenter Observational Study10.1002/art.41943 ↗
34. Real-life evidence of low-dose mepolizumab efficacy in EGPA: A case series10.1186/s12931-021-01775-z ↗
35. Özdel Öztürk, B., Yavuz, Z., Aydın, Ö., Mungan, D., Sin, B.A., Demirel, Y.S., and Bavbek, S. (2022). Effectiveness of low-dose mepolizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): A real-life experience. Int. Arch. Allergy Immunol., online ahead of print.10.1159/000526410 ↗
36. Can Bostan, O., Duran, E., Tuncay, G., Cihanbeylerden, M., Karadag, O., Damadoglu, E., Karakaya, G., and Kalyoncu, A.F. (2022). Sinonasal and respiratory outcomes of eosinophilic granulomatosis with polyangiitis patients receiving 100 mg mepolizumab in real-life clinical practice: 1-year follow up study. J. Asthma, Online ahead of print.10.1080/02770903.2022.2109165 ↗
37. Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis10.1183/23120541.00311-2019 ↗
38. (2022, October 23). Available online: https://www.cinqairhcp.com/globalassets/cinqair-hcp-redesign/prescribing-information.pdf.
39. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: Focus on anti-neutrophil cytoplasm antibody-associated vasculitis10.1136/ard.2006.062711 ↗
40. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis10.1016/j.anai.2021.01.035 ↗
41. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis with Polyangiitis10.3389/fphar.2022.865318 ↗
42. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis10.1016/j.jaip.2020.09.054 ↗
43. Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis10.1016/j.jaip.2020.05.033 ↗
44. Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis10.1183/23120541.00451-2020 ↗
45. (2022, October 23). Available online: https://clinicaltrials.gov/ct2/show/NCT04157348.
46. Valent, P., Klion, A.D., Roufosse, F., Simon, D., Metzgeroth, G., Leiferman, K.M., Schwaab, J., Butterfield, J.H., Sperr, W.R., and Sotlar, K. (2022). Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy, online ahead of print.10.1111/all.15544 ↗
47. Primary eosinophilic gastrointestinal disorders and allergy: Clinical and therapeutic implications10.1002/clt2.12146 ↗
48. (2022, October 23). Available online: https://www.ema.europa.eu/en/documents/product-information/fasenra-epar-product-information_en.pdf.
49. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticarial10.1016/j.anai.2009.11.017 ↗
50. Omalizumab for difficult-to-treat dermatological conditions: Clinical and immunological features from a retrospective real-life experience10.1007/s40261-015-0267-9 ↗